Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 193 articles: HTML format

Single Articles

October 2025
1. COX S, Andreatta K, Hendricks MR, Li J, et al
   Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies.
   J Infect Dis. 2025 Oct 24:jiaf533. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. SESAY FA, Oware K, Violette LR, Donnell D, et al
   Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
   J Infect Dis. 2025 Oct 9:jiaf519. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. MALATESTA S, Carney T, Niemand Wolhuter N, Overbeck V, et al
   Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa.
   J Infect Dis. 2025 Oct 8:jiaf481. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. WARD M, Zumbo P, Joseph Y, Apollon A, et al
   Increased plasmacytoid dendritic cells and inflammation persist in people with HIV years after tuberculosis.
   J Infect Dis. 2025 Oct 7:jiaf499. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. MOONAN PK, Mathew SO, Simecka JW, Weis SE, et al
   Restoring TB-specific immunity in early HIV infection-the dual promise of early antiretroviral and TB preventive treatment.
   J Infect Dis. 2025 Oct 6:jiaf518. doi: 10.1093.
   PubMed    
   
   
   
6. HIRANBURANA N, Sophonphan J, Kerr SJ, Ubolyam S, et al
   NAT2 polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living with HIV: Insights from a Pharmacogenetic-Pharmacokinetic Cohort Study.
   J Infect Dis. 2025 Oct 1:jiaf511. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2025
7. COHEN C, Moore P
   Mechanistic insights into increased vulnerability to respiratory infections in HIV-Exposed Uninfected Infants.
   J Infect Dis. 2025 Sep 30:jiaf494. doi: 10.1093.
   PubMed    
   
   
   
8. BOARDMAN SA, Hetherington C, Hughes T, Cook C, et al
   Viral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies.
   J Infect Dis. 2025 Sep 29:jiaf455. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. KELLY C, Lester JS, Bradshaw D, Bibby DF, et al
   Real-world prevalence of non-integrase INSTI resistance-associated mutations and virological outcomes in people who have recently acquired HIV-1 in the UK.
   J Infect Dis. 2025 Sep 26:jiaf500. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. BENLARBI M, Richard J, Clemente T, Bourassa C, et al
    Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV.
    J Infect Dis. 2025 Sep 24:jiaf461. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. KOGILWAIMATH S, Utay NS
    "Fostemsavir: More Than Meets the Eye".
    J Infect Dis. 2025 Sep 24:jiaf462. doi: 10.1093.
    PubMed    
    
    
    
12. SMITH C, Curtis K, Bonham A, Boyer S, et al
    Maternal Inflammation Likely Drives Impaired Immune Responses to Respiratory Syncytial Virus in HIV-Exposed Uninfected Infants.
    J Infect Dis. 2025 Sep 24:jiaf493. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. ALEMNJI G, Zeh C, Bhairavabhotla R, Wattleworth M, et al
    Implementation of All-inclusive Global Purchasing Agreements for Viral Load and Infant Diagnosis in PEPFAR-Supported Countries.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
14. GOMES DJ, Bancroft EA, Lawal I, Zender N, et al
    Advancing Infection Prevention and Control in the United States PEPFAR Programs.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
15. MATTOCKS L, Celestin N, Francois K, Joseph P, et al
    PEPFAR Investments in Country Data Systems Support HIV Treatment Continuity: An Example From Haiti.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
16. BAPTISTE SL, Barr E, Reid MJA, Campbell DM, et al
    Unpacking the Role, Nature, and Need to Sustain Robust Community Responses in Global Systems.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
17. OKOYE M, Okoi C, Espy N, Mba N, et al
    Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
18. ALEMNJI G, Sangthong A, Espy N, Bartee M, et al
    PEPFAR Laboratory Implementation Strategy as a Component of PEPFAR's 5-Year Strategy.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
19. CHIKWANDA P, Stevens T, Mwangi C, Phiri C, et al
    Leveraging Laboratory Information Management Systems to Support HIV and Other Infectious Diseases Testing in PEPFAR-Supported Countries.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
20. VERANI AR, Samo Gudo E, Chilengi R, Bratton S, et al
    PEPFAR Investments in National Public Health Institutes: HIV Control Through Strong Systems.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
21. BARTEE M, Yessick L, Maloney J, Tomlinson H, et al
    Diagonal Investments in Health Systems: PEPFAR's Approach to Sustaining the HIV Response and Enhancing Global Health Security.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
22. PAN C, Xu H, Huang M, He J, et al
    Mycobacterium tuberculosis PE_PGRS62 protein inhibits type I IFN responses to promote HIV-2 replication by directly interacting with IRF3.
    J Infect Dis. 2025 Sep 17:jiaf484. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. LEONE P, Ferro A, Rolle CP, Lupo S, et al
    VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Anti-drug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
    J Infect Dis. 2025 Sep 2:jiaf450. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
24. CHURIWAL M, Kintu TM, Byamukama O, Bassett IV, et al
    HIV and syphilis coinfection in pregnancy and adverse birth outcomes in Uganda.
    J Infect Dis. 2025 Aug 30:jiaf453. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. LABARILE M, Schoepf IC, Pasin C, Oumelloul MA, et al
    Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study.
    J Infect Dis. 2025 Aug 27:jiaf438. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. RUTAKINGIRWA MK, Ssebambulidde K, Okurut S, Kwizera R, et al
    Cerebrospinal Fluid Mononuclear Cell Phenotype and Activation Predictors of 2-week and 1-year survival among Persons with HIV-Associated Cryptococcal Meningitis.
    J Infect Dis. 2025 Aug 21:jiaf449. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. KELLER MJ, Wang T, Murphy K, Serrano MG, et al
    Cervicovaginal Secretions in Young Women with Bacterial Vaginosis Enhance HIV Infection.
    J Infect Dis. 2025 Aug 21:jiaf444. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. GAO Q, Lan X, Yang F, Yu H, et al
    Prognostic Divergence in HIV/HBV vs. HBV- Associated HCC after Resection: Intrahepatic Pre-S Deletions Mutants and T-cell Depletion under Viral Suppression.
    J Infect Dis. 2025 Aug 14:jiaf433. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. NDHLOVU LC, Giron LB, Galinskas J, Premeaux TA, et al
    Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People Living with HIV.
    J Infect Dis. 2025 Aug 14:jiaf430. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. JUDSON SD, Orkin CM, Gebo K
    Mpox: What Have We Learned and How Do We Better Prepare for the Future?
    J Infect Dis. 2025;232:270-273.
    PubMed     Abstract available
    
    
    
31. PATEL SM, Farirai J, Patel MZ, Boiditswe S, et al
    Alterations of the upper respiratory microbiome among children living with HIV infection in Botswana.
    J Infect Dis. 2025 Aug 12:jiaf429. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. GIANELLA S, Taylor J, Shelton B, Martinez N, et al
    Every Body Has Value: Ending Discriminatory Restrictions on Anatomical Donations.
    J Infect Dis. 2025 Aug 6:jiaf413. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. SAMANDARI T, Achola M, Hutter JN, Mboya G, et al
    Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
    J Infect Dis. 2025 Aug 2:jiaf398. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
34. OBER V, Volk F, Sbierski-Kind J, Gruner E, et al
    Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post-COVID Syndrome.
    J Infect Dis. 2025;232:50-59.
    PubMed     Abstract available
    
    
    
35. KELLEY CF, Weddle A, Agwu A, Bolduc PJ, et al
    Persistence is Resistance: The fight to End the HIV Epidemic Hangs in the Balance.
    J Infect Dis. 2025 Jul 28:jiaf389. doi: 10.1093.
    PubMed    
    
    
    
36. GORDON B, Nyiro JU, Nair H, Sheikh Z, et al
    External validation of paediatric pneumonia and bronchiolitis risk scores to predict mortality in children hospitalised in Kenya: a retrospective cohort study.
    J Infect Dis. 2025 Jul 22:jiaf377. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. LI M, Truong K, Sharma S, Sun B, et al
    Elimination of HIV Reservoirs Harboring Intact Proviruses.
    J Infect Dis. 2025 Jul 16:jiaf373. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. MOHAN H, Nguyen J, Yee A, Laurette EY, et al
    Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir.
    J Infect Dis. 2025 Jul 15:jiaf362. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. MALEYEFF L, Moodie EEM, Golchi S
    SMART Designs: Bridging the Gap Between Clinical Trials and Practice in Infectious Diseases.
    J Infect Dis. 2025;231:1353-1356.
    PubMed     Abstract available
    
    
    
40. FARRELL-SHERMAN A, de la Force N, Prator CA, Valieris R, et al
    Antiviral Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia.
    J Infect Dis. 2025 Jul 9:jiaf367. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. YOON H, Nakouzi AS, Wake RM, Day J, et al
    Comparative analysis of glucuronoxylomannogalactan (GXMGal) and glucuronoxylomannan (GXM) antibody responses and their associations with cryptococcal disease status in people living with HIV.
    J Infect Dis. 2025 Jul 8:jiaf366. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. PEARSON RA, Krish KN, Whatney WE, Jaoko W, et al
    Single-cell transcriptomics reveals depletion and dysregulation of Mycobacterium tuberculosis-specific Th1 and Th17 cells early after acquisition of HIV.
    J Infect Dis. 2025 Jul 3:jiaf354. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
43. BAUERMEISTER JA, Arrington-Sanders R, Coleman-Lewis J, Bertagnolli LN, et al
    Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex with Men: The DREAM ATN Study (ATN 163).
    J Infect Dis. 2025 Jun 28:jiaf349. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. KRAEF C, Omland LH, Porskrog A, Larsen CS, et al
    Risk of cancer after tuberculosis disease among people with HIV in Denmark: a nationwide population-based cohort study.
    J Infect Dis. 2025 Jun 26:jiaf341. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. CHEN J, Zhao L, Zhou X, Mo Y, et al
    Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase IV Clinical Trial.
    J Infect Dis. 2025 Jun 25:jiaf332. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. PERAZZOLO S, Flexner CW, Stephen ZR, Acosta EP, et al
    Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement.
    J Infect Dis. 2025 Jun 24:jiaf319. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. RYCKMAN TS, Hopkins L, Tang L, Biche P, et al
    Molecular epidemiology of Mycobacterium tuberculosis across three distinct geographic sites in South Africa.
    J Infect Dis. 2025 Jun 17:jiaf326. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. NTSHIQA T, Nagudi J, Hamada Y, Copas A, et al
    Risk factors associated with TB infection among household contacts of microbiologically confirmed pulmonary TB patients in three high TB burden countries.
    J Infect Dis. 2025 Jun 17:jiaf320. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. NOVITSKY V, Steingrimsson J, Guang A, Gillani FS, et al
    Newly Diagnosed Individuals in Molecular HIV-1 Clusters in Rhode Island over Three Decades.
    J Infect Dis. 2025 Jun 12:jiaf313. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. HURST JR, Tan DHS, Li A, Khera SS, et al
    Monkeypox virus transcriptional profiles and host responses in skin lesion swabs among individuals with HIV.
    J Infect Dis. 2025 Jun 11:jiaf316. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. YAN A, Kundu S, Samuels DC, Bailin S, et al
    Mitochondrial DNA Haplogroups, Biomarkers of Inflammation and Immune Activation, and Risk of Diabetes in Veterans with and without HIV.
    J Infect Dis. 2025 Jun 9:jiaf304. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. VAN RENSBURG R, Kellermann T, Pillay-Fuentes Lorente V, du Plessis C, et al
    Reduced metformin concentrations in obese women with HIV treated with dolutegravir.
    J Infect Dis. 2025 Jun 5:jiaf305. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
53. ZHENG R, Fuchs EJ, Nimmagadda S, Rohan LC, et al
    Anal Sex and Tenofovir Douche Sequence Impacts Colorectal Distribution of HIV Surrogate and Douche (DREAM-02).
    J Infect Dis. 2025 May 31:jiaf286. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. MORO RN, Johnson JL, Martinson N, Muzanyi G, et al
    Differences in Neutrophil Counts Between African and non-African Countries in two International Clinical Trials.
    J Infect Dis. 2025 May 31:jiaf291. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. ROZEK GM, Yang P, Eby Y, Benner SE, et al
    HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV.
    J Infect Dis. 2025 May 29:jiaf284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. WEGERMANN K, Lucas JE, Dubois L, Mangus R, et al
    Plasma lipid metabolites differentiate metabolic from viral chronic liver disease.
    J Infect Dis. 2025 May 23:jiaf270. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. WILLENBERG L, Freshwater W, Averitt D, Scruggs LH, et al
    The Cost of Silence: A Call to Protect the Future of HIV Research and Care.
    J Infect Dis. 2025 May 22:jiaf267. doi: 10.1093.
    PubMed    
    
    
    
58. YU F, Ma P, Duan J
    Reevaluating the clinical relevance of bacterial vaginosis-associated immune responses in HIV infection.
    J Infect Dis. 2025 May 14:jiaf227. doi: 10.1093.
    PubMed    
    
    
    
59. ROBINSON-PAPP J, Mehta M, Mueller BR, Neupane N, et al
    Gastrointestinal Dysmotility, Autonomic Function and Small Intestinal Bacterial Overgrowth among People with Well-Controlled HIV.
    J Infect Dis. 2025 May 13:jiaf238. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. COLLINS JM, Bobosha K, Narayanan N, Gandhi NR, et al
    A plasma metabolic signature to diagnose pulmonary tuberculosis and monitor treatment response.
    J Infect Dis. 2025 May 8:jiaf240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. CORPUZ JCG
    Tackling HIV Drug Resistance in the Philippines: A Call to Action.
    J Infect Dis. 2025 May 7:jiaf236. doi: 10.1093.
    PubMed    
    
    
    
62. HILLIER SL, Bekker LG, Riddler SA, Hendrix CW, et al
    Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: a Phase 2a Study in Participants at Low Risk for Acquiring HIV-1.
    J Infect Dis. 2025 May 6:jiaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. ROSEN EP, White N, Sykes C, Adamson L, et al
    Heterogeneous antiretroviral drug exposure in male and female genital tract tissues.
    J Infect Dis. 2025 May 5:jiaf225. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
64. ATMAR RL, Lyke KE, Posavad CM, Deming ME, et al
    Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    J Infect Dis. 2025 Apr 29:jiaf176. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. ABDELGAWAD N, Wasserman S, Gausi K, Davis A, et al
    Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.
    J Infect Dis. 2025 Apr 29:jiaf178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. LIU Z, Julius P, Yalcin D, Kang G, et al
    Cellular Tropism and Viral Genetics in Appendix Tissue Reservoirs of Subtype C HIV-1 Infected Aviremic Persons.
    J Infect Dis. 2025 Apr 25:jiaf201. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. PATEL RC, Ndlovu N, Maheria P, Kgoa R, et al
    Pharmacokinetic and clinical associations between doravirine-containing ART and injectable and implantable hormonal contraceptive methods among women living with HIV in South Africa.
    J Infect Dis. 2025 Apr 22:jiaf196. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. BEGRE L, Akotia MK, Wembulua BS, Pandi M, et al
    Circulating HBV RNA and conventional HBV markers in treatment-naive persons with HBV in Senegal.
    J Infect Dis. 2025 Apr 19:jiaf190. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. RONN MM, Chesson HW, Grad YH, Reitsma M, et al
    The influence of epidemiological context on the success of partner notification programs: analysis of gonorrhea transmission dynamics.
    J Infect Dis. 2025 Apr 18:jiaf206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. WANG Y, Brichacek B, Dubrovsky L, Pushkarsky T, et al
    Increased atherosclerosis in HIV-infected humanized mice is caused by a single viral protein, Nef.
    J Infect Dis. 2025 Apr 16:jiaf192. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. LOURENS R, Singh G, Arendse T, Thwaites G, et al
    Tuberculous meningitis across the lifespan.
    J Infect Dis. 2025 Apr 8:jiaf181. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. ERON JJ, Cook PP, Mehrotra ML, Huang H, et al
    Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
    J Infect Dis. 2025 Apr 3:jiaf159. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. MUNOZ-MUELA E, Mejias-Trueba M, Serna-Gallego A, Saborido-Alconchel A, et al
    Mitochondrial disorders after 12 months of HIV-1 preexposure prophylaxis based on tenofovir disoproxil fumarate plus emtricitabine in healthy adults.
    J Infect Dis. 2025 Apr 1:jiaf156. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
74. KLASTRUP V, Gunst JD, Rasmussen TA, Tolstrup M, et al
    Factors influencing virologic control during analytical treatment interruptions in HIV cure trials - a pooled analysis of individual level data.
    J Infect Dis. 2025 Mar 26:jiaf163. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. TOLEDO JP
    Empowering Futures: Restoring T Cell Responses in Children Living with HIV.
    J Infect Dis. 2025 Mar 26:jiaf160. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. ROSTAD CA, Campbell JD, Paulsen GC, Schnyder Ghamloush S, et al
    Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.
    J Infect Dis. 2025 Mar 22:jiaf144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. MADHI SA, Simoes EAF, Acevedo A, Novoa Pizarro JM, et al
    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
    J Infect Dis. 2025;231:e478-e487.
    PubMed     Abstract available
    
    
    
78. SHAIKH MW, Singh S, Giron LB, Zhang L, et al
    Compromised Intestinal Barrier Resilience to Disruption in People with HIV.
    J Infect Dis. 2025 Mar 6:jiaf119. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. MASIA M, Fernandez-Gonzalez M, Ledesma C, Losada-Echeberria M, et al
    Impact of switching to long-acting injectable cabotegravir plus rilpivirine on rectal HIV-1 RNA shedding and implications for transmission risk.
    J Infect Dis. 2025 Mar 5:jiaf117. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. CHESSON HW, Markowitz LE
    Strong Herd Effects of Human Papillomavirus Vaccination.
    J Infect Dis. 2025 Mar 5:jiaf121. doi: 10.1093.
    PubMed    
    
    
    
81. VAN GERWEN OT, Aaron KJ, Kay ES, Siwakoti K, et al
    The Impact of Testosterone Therapy on the Vaginal Microbiota of Transgender Men and Non-Binary People: A Prospective Study.
    J Infect Dis. 2025 Mar 3:jiaf114. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
82. DE GREEF J, Yombi JC, Vincent A, Vandercam B, et al
    Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study.
    J Infect Dis. 2025 Feb 26:jiaf098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. CHOW FC, Kafeero P, Muhumuza P, Nakimbugwe M, et al
    Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults with HIV.
    J Infect Dis. 2025 Feb 17:jiaf089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. YOUNAS M, Gimenez S, Lin YL, Mettling C, et al
    GABA-induced monocytic reactive oxygen species impair CD4 restoration in treated HIV-1 adults.
    J Infect Dis. 2025 Feb 4:jiaf058. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
85. SABO MC, Mustafa S, Saha A, Oyaro B, et al
    Bacterial vaginosis is associated with transcriptomic changes but not higher concentrations of cervical leukocytes in a study of women at high risk for HIV acquisition.
    J Infect Dis. 2025 Jan 28:jiaf049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. MARGOT NA, Jogiraju V, Pennetzdorfer N, Naik V, et al
    Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years.
    J Infect Dis. 2025 Jan 28:jiaf050. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. MACCANN R, Li J, Leon AAG, Negi R, et al
    Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV.
    J Infect Dis. 2025 Jan 24:jiaf043. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. PETERS BA, Xue X, Hanna DB, Wang Y, et al
    Healthy Aging and the Gut Microbiome in People With and Without HIV.
    J Infect Dis. 2025 Jan 22:jiae644. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. ELLIS RJ, Vaida F, Hu K, Dube M, et al
    Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.
    J Infect Dis. 2025 Jan 15:jiaf012. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
90. DABEER S, Tripathi AK, Weiss D, Vikulina T, et al
    Combined Sequential Antiretroviral Therapy-Induced Immune Reconstitution Bone Loss and Estrogen Deficiency Bone Loss are Cumulative in Mice Models.
    J Infect Dis. 2024 Dec 27:jiae643. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. MUKERJI SS, Bachanova P, Park H, Rosen LV, et al
    Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People Living with HIV.
    J Infect Dis. 2024 Dec 26:jiae623. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. OMOLE TE, Nguyen HM, Marcinow A, Oo MM, et al
    Pre-HIV alpha4beta7hi CD4+ T cells and HIV risk among heterosexual individuals in Africa.
    J Infect Dis. 2024 Dec 25:jiae638. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. DIAS GONCALVES LIMA F, Rozemeijer K, van der Zee RP, Dick S, et al
    DNA methylation analysis on anal swabs for anal cancer screening in people living with HIV.
    J Infect Dis. 2024 Dec 24:jiae627. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. DAY CL, Njuguna IN, Cranmer LM, Whatney WE, et al
    Patterns and cofactors of polyfunctional mycobacteria-specific T cell response restoration following 6-month antiretroviral treatment in children living with HIV.
    J Infect Dis. 2024 Dec 18:jiae630. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. MEHTA SR, Wells AB, Cohen C, Campbell A, et al
    Phylodynamics for HIV Prevention: A Miami-Dade Case Study.
    J Infect Dis. 2024 Dec 17:jiae605. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. WILSON GJ, Church LWP, Kelley CF, Robinson ST, et al
    HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
    J Infect Dis. 2024 Dec 13:jiae558. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. GIANELLA S, Yu T, Wang R, Ignacio C, et al
    Viral and Immune Risk Factors of HIV Rebound after Interruption of Antiretroviral Therapy.
    J Infect Dis. 2024 Dec 11:jiae585. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. VANBELLINGHEN MC, Boyd A, Kootstra NA, Schim van der Loeff MF, et al
    A biomarker profile reflective of preserved thymic function is associated with reduced comorbidities in ageing people with HIV: an AGEhIV Cohort analysis.
    J Infect Dis. 2024 Dec 10:jiae603. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. BAILIN SS, Ma S, Perry AS, Terry JG, et al
    The Primacy of Adipose Tissue Gene Expression and Plasma Lipidome in Cardiometabolic Disease in Persons With HIV.
    J Infect Dis. 2024 Dec 9:jiae532. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. WANG J, Genberg BL, Feder K, Kirk GD, et al
     Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
     J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. SACHITHANANDHAM J, Leep-Lazar J, Quinn J, Bowden K, et al
     Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.
     J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2024
102. STRICKLER HD, Usyk M, Eltoum IE, Bachman N, et al
     Case-Control Study of Cervicovaginal Beta-/Gamma-HPV Infection in Women with HIV and Its Relation with Incident Cervical Precancer.
     J Infect Dis. 2024 Nov 27:jiae588. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. VELLAS C, Martres D, Requena M, Nayrac M, et al
     Compartmentalized HIV-1 reservoir in intestinal monocytes/macrophages on antiretroviral therapy.
     J Infect Dis. 2024 Nov 19:jiae557. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. COHEN C, du Plessis M, Martinson N, Moyes J, et al
     A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa.
     J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. ULFHAMMER G, Yilmaz A, Mellgren A, Tyrberg E, et al
     Asymptomatic Cerebrospinal Fluid HIV-1 Escape: Incidence and Consequences.
     J Infect Dis. 2024 Nov 12:jiae555. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. MAGOMBEDZE G, Vendrame E, SenGupta D, Geleziunas R, et al
     Early Viral Dynamics Predict HIV Post-Treatment Control After Analytic Treatment Interruption.
     J Infect Dis. 2024 Nov 8:jiae551. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2024
107. TOBIN NH, Brooker SL, Li F, Coombs RW, et al
     Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women with HIV.
     J Infect Dis. 2024 Oct 31:jiae524. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. BAILON L, Puertas MC, Garcia-Guerrero MC, Moraes-Cardoso I, et al
     Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
     J Infect Dis. 2024 Oct 28:jiae530. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. PAHUS MH, Zheng Y, Olefsky M, Gunst JD, et al
     Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies.
     J Infect Dis. 2024 Oct 23:jiae486. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. ARMISTEAD B, Peters MQ, Houck J, Carlson M, et al
     Exposure to HIV is associated with altered composition of maternal microchimeric T cells in infants.
     J Infect Dis. 2024 Oct 22:jiae521. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. TRUSCELLO E, Wang S, Young J, Sebastiani G, et al
     Changes in hepatic steatosis before and after direct acting antiviral treatment in people living with HIV and Hepatitis C coinfection.
     J Infect Dis. 2024 Oct 17:jiae487. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. RAJAGOPALAN S, Rourke AK, Asare E, Kohlerschmidt DJ, et al
     Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.
     J Infect Dis. 2024 Oct 16:jiae438. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. CHEN J, Chang Y, Wu Y, Tang H, et al
     Trends, Age-Period-Cohort Effects, and Projections in the Incidence and Mortality of HIV/AIDS among the Elderly in China.
     J Infect Dis. 2024 Oct 15:jiae485. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
114. DIRAJLAL-FARGO S, Nikahd M, Ailstock K, Manubolu M, et al
     Changes in the lipidome are associated with immune activation and subclinical vascular disease in youth with HIV in Uganda.
     J Infect Dis. 2024 Sep 27:jiae461. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. NGUYEN HC, Lal KG, Balinsky CA, Hontz RD, et al
     Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023.
     J Infect Dis. 2024;230:645-656.
     PubMed     Abstract available
     
     
     
116. LIN LY, Gantner P, Li S, Su B, et al
     Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
     J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. RUBIN LH, Shirk EN, Pohlenz L, Romero H, et al
     Intact HIV reservoir in monocytes is associated with cognitive function in virally suppressed women with HIV.
     J Infect Dis. 2024 Sep 18:jiae460. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. NGUYEN HT, Chikata T, Zhang Y, Tran GV, et al
     Role of HLA-B*58:01-restricted CD8+ T cells in HIV-1 subtype AE infection.
     J Infect Dis. 2024 Sep 9:jiae448. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. SRINIVASAN S, Richardson BA, Wallis JM, Fiedler TL, et al
     Vaginal Bacteria and Proinflammatory Host Immune Mediators as Biomarkers of Human Immunodeficiency Virus Acquisition Risk Among African Women.
     J Infect Dis. 2024 Sep 9:jiae406. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. DE SCHEERDER MA, Degroote S, Delporte M, Kiselinova M, et al
     In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).
     J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. JANES H, Fisher LH, Kee JJ, Parameswaran L, et al
     Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
     J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. WALKER NF, Schutz C, Ward A, Barr D, et al
     Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis.
     J Infect Dis. 2024 Sep 2:jiae296. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
123. SERRANO-RISQUEZ C, Omar M, Rallon N, Benito JM, et al
     Impact of HLA allele-KIR partners on sexually transmitted HIV-1 infection.
     J Infect Dis. 2024 Aug 29:jiae436. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. AN M, Zheng C, Chen L, Li H, et al
     Sustained Spread of HIV-1 CRF55_01B in Its Place of Initial Origin: Dynamics and Hotspots.
     J Infect Dis. 2024 Aug 29:jiae428. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. CHAIMONGKOL N, Kim DY, Matsushima Y, Durkee-Shock J, et al
     A Decade of Chronic Norovirus Infection Surveillance at the NIH Clinical Research Center: Clinical Characteristics, Molecular Epidemiology, and Replication.
     J Infect Dis. 2024 Aug 29:jiae440. doi: 10.1093.
     PubMed     Abstract available
     
     
     
126. SERRANO-VILLAR S, Gala A, Bacchetti P, Hoh R, et al
     Galectin-9 Levels as a Potential Predictor of Intact HIV Reservoir Decay.
     J Infect Dis. 2024 Aug 28:jiae426. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. OKAFOR EC, Mukaremera L, Hullsiek KH, Engen N, et al
     CSF Cytokines and Chemokines Involved in Cytotoxic Cell Function and Risk of Acute 14-Day Mortality in Persons with Advanced HIV and Cryptococcal Meningitis.
     J Infect Dis. 2024 Aug 28:jiae421. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. PATEL D, Mulatu MS, Wang G, May AC, et al
     CDC-Funded HIV Testing Services Outcomes in Ending the HIV Epidemic in the U.S. (EHE) and Non-EHE Jurisdictions, 2021.
     J Infect Dis. 2024 Aug 28:jiae430. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. YE J, Dong Y, Lan Y, Chen J, et al
     Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.
     J Infect Dis. 2024 Aug 27:jiae303. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. YE J, Lan Y, Wang J, Feng Y, et al
     Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China.
     J Infect Dis. 2024 Aug 26:jiae302. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. DOYLE RM, Kannambath S, Pittman A, Goliath R, et al
     Ex vivo host transcriptomics during Cryptococcus neoformans, Cryptococcus gattii, and Candida albicans infection of PBMCs from South African volunteers.
     J Infect Dis. 2024 Aug 19:jiae410. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. D'ENTREMONT-HARRIS M, Ramsey TD, Pelletier E, Goodall B, et al
     Reply to Antinori and Bausch-Jurken.
     J Infect Dis. 2024;230:524-526.
     PubMed    
     
     
     
133. DESISTO CL, Winer RL, Querec TD, Dada D, et al
     Vaccine effectiveness against anal HPV among men who have sex with men aged 18-45 years attending sexual health clinics in three United States cities, 2018-2023.
     J Infect Dis. 2024 Aug 8:jiae394. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
134. ABARA WE, Kirkcaldy RD, Bernstein KT, Galloway E, et al
     Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis.
     J Infect Dis. 2024 Jul 31:jiae383. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. TANTALO LC, Luetkemeyer A, Lieberman NAP, Nunley BE, et al
     Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis.
     J Infect Dis. 2024 Jul 27:jiae381. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. ELLIOT ER, Polli JW, Patel P, Garside L, et al
     Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
     J Infect Dis. 2024;230:e34-e42.
     PubMed     Abstract available
     
     
     
137. ALLEN LI, Fraser H, Stone J, McAuley A, et al
     Testing and Treatment Interventions in Community Settings Key to Controlling a Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Glasgow: A Modeling Study.
     J Infect Dis. 2024;230:e48-e59.
     PubMed     Abstract available
     
     
     
138. JOHNSON JA, Li JF, Politch JA, Lipscomb JT, et al
     HIV Immunocapture Reveals Particles Expressed in Semen Under Integrase Strand Transfer Inhibitor-Based Therapy Are Largely Myeloid Cell-Derived and Disparate.
     J Infect Dis. 2024;230:78-85.
     PubMed     Abstract available
     
     
     
139. BURDORF RM, Zhou S, Amon C, Long N, et al
     Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes.
     J Infect Dis. 2024;230:86-94.
     PubMed     Abstract available
     
     
     
140. WANG X, Zhang Y, Xiao J, Song C, et al
     Effect of Vaginal Microecological Disorders on the Increased Risk of Abnormal Cervical Cytology Among Women With Human Immunodeficiency Virus in China.
     J Infect Dis. 2024;230:61-66.
     PubMed     Abstract available
     
     
     
141. VAN DE WEG CAM, Thomazella MV, Marmorato MP, Correia CA, et al
     Levels of Angiopoietin 2 Are Predictive for Mortality in Patients Infected With Yellow Fever Virus.
     J Infect Dis. 2024;230:e60-e64.
     PubMed     Abstract available
     
     
     
142. COMBES JD, Didelot JM, Radenne S, Zaegel-Faucher O, et al
     Cumulative Detection of Anal High-Grade Squamous Intraepithelial Lesions Over 2-Year Follow-up in Men Who Have Sex With Men Living With Human Immunodeficiency Virus in France.
     J Infect Dis. 2024;230:55-60.
     PubMed     Abstract available
     
     
     
143. VAN TEIJLINGEN NH, van Smoorenburg MY, Sarrami-Forooshani R, Zijlstra-Willems EM, et al
     Prevotella timonensis Bacteria Associated With Vaginal Dysbiosis Enhance Human Immunodeficiency Virus Type 1 Susceptibility Of Vaginal CD4+ T Cells.
     J Infect Dis. 2024;230:e43-e47.
     PubMed     Abstract available
     
     
     
144. WILCOX CS, Herbert C, Wang C, Ma Y, et al
     Signals From Inflamed Perivascular Adipose Tissue Contribute to Small-Vessel Dysfunction in Women With Human Immunodeficiency Virus.
     J Infect Dis. 2024;230:67-77.
     PubMed     Abstract available
     
     
     
145. LANTZ A, Kiweewa Matovu F, Johnson R, Isingel E, et al
     Female genital tract host factors and tenofovir and lamivudine active metabolites.
     J Infect Dis. 2024 Jul 24:jiae372. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. GILS T, Hella J, Jacobs BKM, Sossen B, et al
     A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries.
     J Infect Dis. 2024 Jul 24:jiae374. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. ALESSANDRINI J, Cox J, de Pokomandy A, Hart TA, et al
     Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019.
     J Infect Dis. 2024 Jul 23:jiae345. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. AUNG S, Novitsky V, Steingrimsson J, Gillani FS, et al
     Acquired Human Immunodeficiency Virus Type 1 Drug Resistance in Rhode Island, USA, 2004-2021.
     J Infect Dis. 2024 Jul 23:jiae344. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. BLOOM N, Ramirez SI, Cohn H, Parikh UM, et al
     SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
     J Infect Dis. 2024 Jul 22:jiae371. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. AGRAWAL P, Giron LB, Singh S, Haw NJ, et al
     Pre-pandemic Metabolic Correlates of COVID-19 Severity and Long COVID Incidence in People Living with HIV.
     J Infect Dis. 2024 Jul 16:jiae362. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. BLENKINSOP A, Pantazis N, Kostaki EG, Sofocleous L, et al
     Sources of Human Immunodeficiency Virus Infections Among Men Who Have Sex With Men With a Migration Background: A Viral Phylogenetic Case Study in Amsterdam, The Netherlands.
     J Infect Dis. 2024 Jul 8:jiae267. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
152. REID TB, Godornes C, Campbell VL, Laing KJ, et al
     Treponema pallidum Periplasmic and Membrane Proteins Are Recognized by Circulating and Skin CD4+ T Cells.
     J Infect Dis. 2024 Jun 27:jiae245. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. WANG F, Rademeyer K, Namuju OC, Abdusalaamu K, et al
     Post-mortem analysis of dolutegravir, tenofovir, lamivudine and efavirenz penetration in multiple CNS compartments.
     J Infect Dis. 2024 Jun 20:jiae325. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. CHOW EPF, Stevens K, De Petra V, Chen MY, et al
     Prevalence of cefixime-resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022.
     J Infect Dis. 2024 Jun 15:jiae313. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. JACOBSON DL, Crider KS, DeMarrais P, Brummel S, et al
     Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
     J Infect Dis. 2024 Jun 15:jiae308. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. RUSHMORE J, Learner ER, Bernstein KT
     Expanding the Evidence Base for Improving Sexual Health Among Transgender Communities: The Importance of Rigorous Epidemiologic Studies.
     J Infect Dis. 2024;229:1603-1605.
     PubMed    
     
     
     
157. AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al
     Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
     J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
158. KANKAKA EN, Poon AFY, Quinn TC, Chang LW, et al
     Impact of variable sampling on estimates of HIV-1 reservoir formation dates.
     J Infect Dis. 2024 May 31:jiae294. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. DURSTENFELD MS, Wilson MP, Jankowski CM, Ditzenberger GL, et al
     Chronotropic Incompetence among People with HIV Improves with Exercise Training in the Exercise for Healthy Aging Study.
     J Infect Dis. 2024 May 28:jiae284. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. SPRINGER YP, Tompkins ML, Newell K, Jones M, et al
     Characterizing the etiology of recurrent tuberculosis using whole genome sequencing-Alaska, USA, 2008-2020.
     J Infect Dis. 2024 May 24:jiae275. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. ALLEN LI, Fraser H, Stone J, McAuley A, et al
     Testing and Treatment Interventions in Community Settings Key to Controlling a Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Glasgow: A Modeling Study.
     J Infect Dis. 2024 May 22:jiae206. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. MCCLUSKEY SM, Muyindike WR, Nanfuka V, Omoding D, et al
     Population Effectiveness of Dolutegravir Implementation in Uganda - A Prospective Observational Cohort Study (DISCO): 48-week Results.
     J Infect Dis. 2024 May 16:jiae260. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. SMITH CL, Didion E, Aung H, Tamilselvan B, et al
     Longitudinal analysis of nursing home residents' T cell responses after SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2 infection history.
     J Infect Dis. 2024 May 14:jiae234. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. MASIA M, Garcia JA, Garcia-Abellan J, Padilla S, et al
     Distinct gut microbiota signatures associated with progression of atherosclerosis in people living with HIV.
     J Infect Dis. 2024 May 14:jiae243. doi: 10.1093.
     PubMed     Abstract available
     
     
     
165. MOTSOENENG BM, Dhar N, Nunes MC, Krammer F, et al
     Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women.
     J Infect Dis. 2024 May 14:jiae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. SERRANO-VILLAR S, Martinez E
     The Gut Microbiome: Another Piece in the Puzzle of HIV-Associated Atherosclerosis.
     J Infect Dis. 2024 May 14:jiae244. doi: 10.1093.
     PubMed    
     
     
     
167. PATHELA P, Townsend MB, Kopping EJ, Tang J, et al
     Serological Evidence of Mpox Virus Infection During Peak Mpox Transmission in New York City, July to August 2022.
     J Infect Dis. 2024 May 13:jiae181. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. NICHOLSON LK, Kofonow JM, Robertson CE, Wright T, et al
     Clinical and Microbial Determinants of Upper Respiratory Colonization with Streptococcus pneumoniae and Native Microbiota in People with HIV-1 and Control Adults.
     J Infect Dis. 2024 May 8:jiae247. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. SINGH OP, Chaubey R, Kushwaha AK, Fay MP, et al
     Visceral Leishmaniasis-Human Immunodeficiency Virus-Coinfected Patients Are Highly Infectious to Sandflies in an Endemic Area in India.
     J Infect Dis. 2024 May 7:jiae156. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. WU L, Kinuthia J, Anderson PL, Baeten JM, et al
     Drug concentrations in hair and dried blood spots as PrEP adherence metrics during pregnancy and postpartum.
     J Infect Dis. 2024 May 3:jiae208. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. BERKOWITZ SA
     The Benefits of Medically Tailored Meals for People Living with HIV.
     J Infect Dis. 2024 May 2:jiae196. doi: 10.1093.
     PubMed    
     
     
     
172. PALAR K, Sheira LA, Frongillo EA, O'Donnell AA, et al
     Food is Medicine for HIV: Improved health and hospitalizations in the Changing Health through Food Support (CHEFS-HIV) pragmatic randomized trial.
     J Infect Dis. 2024 May 2:jiae195. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
173. GILLIS N, Dickey BL, Colin-Leitzinger C, Tang YH, et al
     Clonal hematopoiesis in patients with HIV and cancer.
     J Infect Dis. 2024 Apr 24:jiae212. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. RIDDLER SA, Kelly CW, Hoesley CJ, Ho KS, et al
     A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
     J Infect Dis. 2024 Apr 24:jiae211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
175. MORO RN, Mehaffy C, De P, Phillips E, et al
     Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
     J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al
     Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
     J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093.
     PubMed     Abstract available
     
     
     
177. MURENZI G, Kim HY, Mivumbi JP, Gasana J, et al
     Incidence, Clearance and Persistence of Penile High-Risk Human Papillomavirus among Rwandan Men who have Sex with Men.
     J Infect Dis. 2024 Apr 16:jiae190. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
     Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
     J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. VAN TEIJLINGEN NH, van Smoorenburg MY, Sarrami-Forooshani R, Zijlstra-Willems EM, et al
     Prevotella timonensis bacteria associated with vaginal dysbiosis enhance HIV-1 susceptibility of vaginal CD4+ T cells.
     J Infect Dis. 2024 Apr 4:jiae166. doi: 10.1093.
     PubMed     Abstract available
     
     
     
180. BAR ZIV O, Cahn A, Jansen T, Istomin V, et al
     Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living with HIV- Evaluation of Clinical and Microbiome Parameters.
     J Infect Dis. 2024 Apr 1:jiae167. doi: 10.1093.
     PubMed     Abstract available
     
     
     
181. BERENGUER J, Jarrin I, Bellon JM, Diez C, et al
     Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients with HIV.
     J Infect Dis. 2024 Apr 1:jiae168. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
182. XIU F, Flores Anato JL, Cox J, Grace D, et al
     Characteristics of the Sexual Networks of Men Who Have Sex With Men in Montreal, Toronto, and Vancouver: Insights from Canada's 2022 Mpox Outbreak.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
183. SNYDER RE, Saadeh K, Tang EC, Johnson KA, et al
     Sexual Exposures Associated With Mpox Infection: California, November 2022 to June 2023.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
184. OLSSON O, Sokilde R, Tesfaye F, Karlson S, et al
     Tuberculosis disease is associated with elevated plasma ribonuclease activity in antiretroviral treatment-naive people with HIV.
     J Infect Dis. 2024 Mar 25:jiae143. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. ZEEB M, Frischknecht P, Huber M, Schenkel CD, et al
     Genetic diversity from proviral DNA as a proxy for time since HIV-1 infection.
     J Infect Dis. 2024 Mar 20:jiae149. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. GRUNER E, Grossegesse M, Stern D, Ober V, et al
     Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
     J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. BURDORF R, Zhou S, Amon C, Long N, et al
     Impact Of Low-Frequency HIV-1 Drug Resistance Mutations On Antiretroviral Therapy Outcomes.
     J Infect Dis. 2024 Mar 11:jiae131. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. COLON W, Oriol Mathieu V, Hural J, Hattingh L, et al
     HIV Diagnostics and Vaccines: It Takes Two to Tango.
     J Infect Dis. 2024 Mar 7:jiae113. doi: 10.1093.
     PubMed     Abstract available
     
     
     
189. WILCOX CS, Herbert C, Wang C, Ma Y, et al
     Signals From Inflamed Perivascular Adipose Tissue Contribute to Small Vessel Dysfunction in Women Living With the Human Immunodeficiency Virus.
     J Infect Dis. 2024 Mar 1:jiae094. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
190. XIAO G, Huang W, Zhong Y, Ou M, et al
     Uncovering the Bronchoalveolar Single-Cell Landscape of Patients With Pulmonary Tuberculosis With Human Immunodeficiency Virus Type 1 Coinfection.
     J Infect Dis. 2024 Feb 27:jiae042. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
     Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
     J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. COLLAZOS J, Asensi V
     Non-invasive liver fibrosis markers in the evaluation of fibrosis regression after direct-acting antiviral (DAA) therapy.
     J Infect Dis. 2024 Feb 23:jiae095. doi: 10.1093.
     PubMed    
     
     
     
193. RANDALL KL, Flesch IEA, Mei Y, Miosge LA, et al
     DOCK2-deficiency causes defects in anti-viral T cell responses and impaired control of herpes simplex virus infection.
     J Infect Dis. 2024 Feb 15:jiae077. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.